Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 positive |
| Therapy | ALK201 |
| Indication/Tumor Type | stomach cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 positive | stomach cancer | predicted - sensitive | ALK201 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, ALK201 induced antibody-dependent cellular cytotoxicity in gastric cancer cells expressing FGFR2b in culture and inhibited tumor growth in a cell line xenograft and patient-derived xenograft (PDX) model (Cancer Res (2025) 85 (8_Supplement_2): LB227). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract LB227: ALK201, a first-in-class FGFR2b-targeting antibody-drug conjugate for patients with FGFR2b+ gastric cancer and other solid tumors | Full reference... |